Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
As previously announced on August 19, 2024, Titan and TalenTec have entered into a Merger and Contribution and Share Exchange Agreement (the 'Merger Agreement') regarding a business combination, pursuant to which Titan will be combined with TalenTec in a 'reverse merger' transaction (the 'Business Combination').
The Form F-4 was filed by Black Titan Corporation, the holding company under which the businesses will combine, and is available through the SEC's website at www.sec.gov under the name 'Black Titan Corporation.' The registration statement has not been declared effective by the SEC and the information in the preliminary proxy statement/prospectus is not complete and may be changed.
The Business Combination is subject to approval by Titan stockholders and the satisfaction of other customary closing conditions and is expected to close in the third quarter of 2025 although there can be no assurance thereof.
Important Information About the Business Combination and Where to Find It
This communication is being made in respect of the proposed Business Combination transaction between Titan and TalenTec. The proposed transaction will be submitted to the stockholders of Titan for their consideration and approval. In connection with the proposed transaction, Black Titan Corporation has filed with the SEC a registration statement on Form F-4 that includes a preliminary proxy statement/prospectus (a 'Proxy Statement/Prospectus'). After the registration statement has been declared effective by the SEC, a definitive Proxy Statement/Prospectus will be mailed to Titan's stockholders as of a record date to be established by Titan's board of directors for voting on the Business Combination. Titan may also file other relevant documents regarding the Business Combination with the SEC. Titan's stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement/Prospectus and any amendments thereto and, once available, the definitive Proxy Statement/Prospectus, in connection with Titan's solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Business Combination, because these documents will contain important information about Titan, TalenTec and the Business Combination. Stockholders of Titan may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC regarding the Business Combination and other documents filed with the SEC, without charge, at the SEC's website located at www.sec.gov or by directing a request to: Titan's Chief Executive Officer at 10 East 53rd St., Suite 3001, New York, NY 10022.
Participants in the Solicitation
Titan, TalenTec and their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies of Titan's stockholders in connection with the potential transactions described herein under the rules of the SEC. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Titan's and TalenTec's officers and directors in the registration statement on Form F-4 to be filed with the SEC and will also be contained in the Proxy Statement/Prospectus relating to the proposed transactions when it is filed with the SEC. These documents may be obtained free of charge from the sources indicated above.
Forward-Looking Statements
The disclosure herein may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include, without limitation, Titan's expectations with respect to future performance, ability to consummate the Business Combination and ability to recognize the anticipated benefits of the Business Combination; costs related to the proposed Business Combination; the satisfaction of the closing conditions to the Business Combination; the timing of the closing, if any, of the Business Combination; global economic conditions; geopolitical events and regulatory changes; and other risks and uncertainties indicated from time to time in filings with the SEC. Additional information concerning these and other risk factors is contained in Titan's most recent filings with the SEC and will be contained in the Form F-4 and other filings to be filed as result of the transactions described above. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
No Offer or Solicitation
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Business Combination, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This press release does not constitute either advice or a recommendation regarding any securities. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom.
Media & Investor Contacts:
Chay Weei Jye
Chief Executive Officer
(786) 769-7512
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Newmont (NEM) Surges 36% Over Last Quarter Following Strong Q2 2025 Earnings
Newmont recently announced its second quarter 2025 results, revealing a substantial increase in sales and net income compared to the prior year. The company also declared a quarterly dividend, authorized a significant share repurchase program, and completed a lease renewal in Ghana. Despite a decline in gold production, these developments likely bolstered investor confidence, contributing to the company's 36% share price increase over the last quarter. This upward movement aligns broadly with the market's positive trend, which included record highs in the Nasdaq and increased overall investor optimism amidst additional stock buyback activity and dividends within the sector. Every company has risks, and we've spotted 1 warning sign for Newmont you should know about. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. With Newmont's latest results showing a boost in sales and net income, the company's operational and strategic developments could reinforce its current narrative of resilience, focusing on gold demand and asset synergies. However, despite a recent uptick in its share price—36% this past quarter—the stock has achieved a total shareholder return of 63.75% over the past three years. This long-term performance reflects a complex mix of operational efficiency and market conditions, aligning with the company's efforts to maintain stability amidst fluctuating gold production rates. Over the last year, Newmont's performance has outpaced the broader US Metals and Mining industry, which returned 24.1%. This indicates a strong relative positioning, likely aided by the company's proactive engagement in shareholder returns through dividends and share repurchase programs. As for revenue and earnings forecasts, the recent lease renewal in Ghana and other long-term initiatives might offer sustained revenue support, though the decline in gold production introduces a risk to achieving the expected 1.6% annual revenue growth over the next three years. Currently trading at US$68.98, Newmont's share price aligns closely with the consensus price target of US$70.36, suggesting the market views the stock as fairly priced given current conditions. The modest price differential indicates skepticism about substantial immediate upside but acknowledges the potential for incremental value in alignment with forecasted earnings of US$6.3 billion by 2028. As such, the current developments signal a stable, though cautious, investor sentiment focused on sustainable growth. Unlock comprehensive insights into our analysis of Newmont stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NEM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
U.S. Spot XRP ETFs: Five Possible Reasons Behind BlackRock's Hesitation to File for One
BlackRock has made bold moves into bitcoin and ether ETFs, but on Friday, the asset manager said it had no immediate plans to file for a spot XRP exchange-traded fund (ETF), dashing the community's hopes that its entry could help extend XRP's 2025 rally. This statement — made the day after the U.S. Securities and Exchange Commission (SEC) and Ripple Labs jointly asked an appeals court to dismiss their respective appeals, signaling an end to their nearly five-year legal battle — has left investors questioning why BlackRock remains on the sidelines. Invest in Gold Thor Metals Group: Best Overall Gold IRA Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase American Hartford Gold: #1 Precious Metals Dealer in the Nation While several asset managers, including ProShares, Grayscale, and Bitwise, have filed for XRP ETFs since late 2024, BlackRock's absence is notable, especially given its dominance in the bitcoin and ether ETF markets. Here are five reasons why BlackRock appears in no hurry to launch a spot XRP ETF, despite the XRP community's anticipation of a demand-driven price surge. First, BlackRock has cited limited client interest in cryptocurrencies beyond BTC and ETH. Back in March 2024, Robert Mitchnick, the asset manager's head of digital assets, said that there's a misconception that BlackRock will have a "long tail" of other crypto services. "I can say that for our client base, bitcoin is overwhelmingly the No. 1 focus and a little bit ethereum," he said during a fireside chat at the inaugural Bitcoin Investor Day conference in New York on March 22. Second, BlackRock's strategic caution around regulatory uncertainty plays a role. Although XRP sales on public exchanges are deemed non-securities, the broader regulatory framework for altcoins remains murky. BlackRock may be waiting for clearer SEC guidelines before entering the altcoin ETF space. The firm's conservative approach contrasts with competitors like ProShares, which filed for a spot XRP ETF in January 2025 alongside leveraged and futures-based XRP ETFs, the latter tracking XRP futures contracts rather than the token's spot price. Third, BlackRock may see diminishing returns in pursuing a spot XRP ETF given the crowded field. As of August 2025, at least seven firms, including Grayscale, Franklin Templeton and 21Shares, have a pending spot XRP ETF application. Fourth, the XRP community's expectations of a price surge may not align with BlackRock's data-driven strategy. Polymarket odds for the SEC approving a spot XTP ETF in 2025 stand at 77%. BlackRock's tokenized money market fund on Ethereum and Solana shows blockchain interest, but XRP's smaller market footprint may not justify the operational costs of a new ETF. Finally, BlackRock's global perspective prioritizes markets where XRP demand is less pronounced. While the XRP community, active on platforms like X, anticipates a spot ETF driving demand, much of XRP's trading volume comes from Asia, where BlackRock's ETF presence is less dominant. At press time, XRP was trading around $3.1852, down 3.92% in the past 24 hours, according to CoinDesk Data. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Where Will Walgreens Be in 1 Year?
Key Points Walgreens has agreed to be taken private for $11.45 per share. The deal has been approved by shareholders, and the stock is trading for slightly more than the takeover price. There's a nuance to the buyout story that could lead to an additional payout of as much as $3 per share. 10 stocks we like better than Walgreens Boots Alliance › Walgreens Boots Alliance (NASDAQ: WBA) has been a difficult stock to love for a few years, thanks to multiple corporate missteps. It got so bad that the board decided the best course of action was to effect a turnaround under private hands. That deal means that Walgreens won't be a publicly traded company a year from now. But that isn't the whole story, and more aggressive investors might still be interested in the stock because of a unique nuance of the take-private transaction. Here's what you need to know. From industry giant to going private There are only a handful of large pharmacy retailers, and Walgreens is one of them. For many years it was a growth business, but eventually the market became saturated. Often there was a Walgreens on one corner and one of its competitors just across the street. It's not shocking that growth stalled out throughout the sector. What happened next was that Walgreens looked for other ways to keep growing its business. It tried to buy into the pharmacy benefits management business, but that didn't go as well as hoped. And then it started to build out a healthcare clinic operation, but that didn't go as well as hoped. This company, which was on track to become a Dividend King, ended up cutting and then eliminating its dividend (the elimination came after the take-private agreement came about). Walgreens had recently been working to right-size its business, including closing locations. However, the revamp is likely to be a large undertaking that will be difficult to effect in the public markets. Investors don't like it when companies shrink, and that's exactly what Walgreens is in the process of doing. So, in early March, it agreed to be taken private by Sycamore Partners Management for $11.45 per share. The transaction is likely to close sometime in the second half of 2025. Why is Walgreens trading for more than the deal price? Normally in a takeover situation, the stock of the company being acquired trades for slightly less than the takeover price. That's because there is always a risk that the deal falls apart. However, Walgreens' shares are trading hands for slightly more than the takeover price, which suggests that there is something odd going on here. The wrinkle is that Sycamore Partners is planning on selling Walgreens' medical clinic business. And it will give Walgreens shareholders a chit that could be worth up to $3 per share, depending on the sales price it gets for the clinic business. So investors that are paying over $11.45 per share for Walgreens right now are, essentially, buying that chit, since they are locking in a loss on the Walgreens shares. There's just one problem. There is no timeline for the sale of the clinic business. And there is no guarantee on the price that Sycamore Partners will extract from the buyer. So the $3 chit could be worthless or, conversely, the length of time it takes to see any money could be very long, reducing the time value of the potential profit. There's just no way to tell what the outcome will be. And, as such, buying Walgreens today is not something that most investors should do, particularly if they are conservative by nature. More aggressive types that like special situations may like it, since the clinic business probably does have some value. But it is still a high-risk play that has a maximum upside of around 25%. That sounds like a lot, and it is, but only if the cash arrives quickly. Walgreens will be gone in a year, but not forgotten In one year, Walgreens will no longer be a public company. But it will linger in the minds of investors because of the $3 chit tied to the sale of the medical clinic business. That said, in the long term, it seems highly likely that Walgreens will eventually go public again -- with completely different shares -- hopefully with a better industry position. However, only aggressive investors should be looking at Walgreens right now. Should you buy stock in Walgreens Boots Alliance right now? Before you buy stock in Walgreens Boots Alliance, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Walgreens Boots Alliance wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Where Will Walgreens Be in 1 Year? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
